One-step solid-oil-water emulsion for sustained bioactive ranibizumab release
| Autor: | Hui Yee Chua, Yuan Siang Lui, Peter R. Preiser, Ramya Bhuthalingam, Rupesh Agrawal, Subbu S. Venkatraman, Tina T. Wong |
|---|---|
| Přispěvatelé: | School of Materials Science & Engineering, School of Biological Sciences, Interdisciplinary Graduate School (IGS), Institute for Health Technologies |
| Rok vydání: | 2018 |
| Předmět: |
Drug
genetic structures media_common.quotation_subject Pharmaceutical Science Angiogenesis Inhibitors 02 engineering and technology Pharmacology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Polylactic Acid-Polyglycolic Acid Copolymer Ranibizumab Oil water emulsion medicine Particle Size media_common Materials [Engineering] Chemistry PLGA 021001 nanoscience & nanotechnology Microspheres Bioactive Delayed-Action Preparations 030221 ophthalmology & optometry Emulsions 0210 nano-technology medicine.drug |
| Zdroj: | Expert Opinion on Drug Delivery. 15:1143-1156 |
| ISSN: | 1744-7593 1742-5247 |
| Popis: | Background: The advent of therapeutic proteins highlights the need for delivery systems that protect and extend the duration of its action. Ranibizumab-VEGF is one such drug used for treating wet AMD. This paper describes a facile method to sustain bioactive ranibizumab release from PLGA-based particles. Methods: Two emulsion techniques were explored namely: water-in-oil-in-water (WOW) and solid-in-oil-in-water (SOW) emulsion. The bioactivity of ranibizumab was evaluated by comparing its binding capability to VEGF, measured with ELISA to total protein measured by microBCA. Results: During the emulsion process, contact of ranibizumab with the water-oil interface is the main destabilizing factor and this can be prevented with the use of amphiphilic PVA and solid-state protein in WOW and SOW emulsion respectively. In vitro release of the ranibizumab-loaded particles indicated that a 15-day release could be achieved with SOW particles while the WOW particles generally suffered from a burst release. Released ranibizumab was capable of inhibiting endothelial cell growth indicating its retention of bioactivity. The suppression of burst release from the SOW particles was attributed to the relatively smooth surface morphology of the SOW microparticles. Conclusions: The use of SOW encapsulation in modulating ranibizumab release while maintaining their bioactivity has been highlighted. MOE (Min. of Education, S’pore) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|